GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » 4Front Ventures Corp (OTCPK:FFNTF) » Definitions » Equity-to-Asset
中文

4Front Ventures (4Front Ventures) Equity-to-Asset

: -0.20 (As of Dec. 2023)
View and export this data going back to 2010. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. 4Front Ventures's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-51.5 Mil. 4Front Ventures's Total Assets for the quarter that ended in Dec. 2023 was $264.0 Mil. Therefore, 4Front Ventures's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -0.20.

The historical rank and industry rank for 4Front Ventures's Equity-to-Asset or its related term are showing as below:

FFNTF' s Equity-to-Asset Range Over the Past 10 Years
Min: -61.56   Med: -0.18   Max: 0.66
Current: -0.2

During the past 13 years, the highest Equity to Asset Ratio of 4Front Ventures was 0.66. The lowest was -61.56. And the median was -0.18.

FFNTF's Equity-to-Asset is ranked worse than
91.26% of 1087 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs FFNTF: -0.20

4Front Ventures Equity-to-Asset Historical Data

The historical data trend for 4Front Ventures's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4Front Ventures Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.16 0.21 0.15 0.08 -0.20

4Front Ventures Quarterly Data
Jan19 Apr19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.05 0.02 -0.19 -0.20

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, 4Front Ventures's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


4Front Ventures Equity-to-Asset Distribution

For the Drug Manufacturers industry and Healthcare sector, 4Front Ventures's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where 4Front Ventures's Equity-to-Asset falls into.



4Front Ventures Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

4Front Ventures's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-51.502/263.954
=-0.20

4Front Ventures's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-51.502/263.954
=-0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


4Front Ventures  (OTCPK:FFNTF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


4Front Ventures Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of 4Front Ventures's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


4Front Ventures (4Front Ventures) Business Description

Traded in Other Exchanges
Address
5060 North 40th Street, Suite 120, Phoenix, AZ, USA, 85018
4Front Ventures Corp is a Canadian-based company. It is engaged in the cultivation, processing, extracting, manufacturing, and distribution of cannabis products. It operates in two segments: THC Cannabis and CBD Wellness. The THC Cannabis segment engages in the production and cultivation of THC cannabis, manufacturing and distribution of cannabis products to own dispensaries and third-party retail customers. The CBD Wellness segment encompasses the production and sale of CBD products to third-party customers.
Executives
Leonid Gontmakher director, officer: Chief Executive Officer 5060 N. 40TH STREET, SUITE 120, PHOENIX AZ 85018
Nicole Frederick officer: See Remarks C/O 4FRONT VENTURES CORP., 7010 E. CHAUNCEY LANE STE. 235, PHOENIX AZ 85054
Kristopher Krane director 5060 N. 40TH STREET, SUITE 120, PHOENIX AZ 85018
David Ryan Daily director 5060 N 40TH STREET STE 120, PHOENIX AZ 85018
Roman Tkachenko director 5060 N 40TH STREET STE 120, PHOENIX AZ 85018
Karl Chowscano other: Consultant 5060 N. 40TH STREET, SUITE 120, PHOENIX AZ 85018
Chetan Gulati director 28 REICHERT CIRCLE, WESTPORT CT 06880
Keith Edward Adams officer: Chief Financial Officer 108 S. WETHERLY DRIVE, UNIT 4, LOS ANGELES CA 90048
Robert E Hunt director C/O GROWLIFE, INC., 20301 VENTURA BLVD., SUITE 126, WOODLAND HILLS CA 91364
Amit Ramanlal Patel director 3305 PINE AVENUE, MANHATTAN BEACH CA 90266
Kathi P Lentzsch director 5060 N 40TH STREET STE 120, PHOENIX AZ 85018
Andrew Thut officer: Chief Investment Officer 5060 N. 40TH STREET, SUITE 120, PHOENIX AZ 85018
Joseph R Feltham officer: Chief Operating Officer 5060 N. 40TH STREET, STE 120, PHOENIX AZ 85018
Eric J. Rey director ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Nicolle Dorsey officer: Chief Financial Officer C/O REAL GOODS SOLAR, INC., 110 16TH STREET, 3RD FLOOR, DENVER CO 80202